Flatiron Health renews NCCN real-world oncology data collaboration through 2028, deploys Flatiron Telescope
Flatiron renews its NCCN real-world oncology data collaboration through 2028 and layers Flatiron Telescope on top — the AI intelligence work sits with Flatiron, not with the 34 academic cancer centers whose EHRs supply the substrate.
Where the rake sits
Flatiron keeps the pharma-facing cash rake (RWE sold to 20+ oncology developers) because it owns both the curation pipeline and the Telescope platform; NCCN's rake is in-kind — member tooling and research access — which is a defensible trade for a non-profit alliance but leaves cash economics with Flatiron.
What happened
- Renewal extends the Flatiron–NCCN real-world oncology data collaboration through 2028.
- NCCN is an alliance of 34 US cancer centers, founded January 1995, headquartered in Plymouth Meeting, PA.
- Flatiron Health was founded in 2012 and acquired by Roche for $1.9B in 2018; it now operates as an independent Roche affiliate.
- Flatiron Telescope, Flatiron's AI intelligence layer, is deployed as part of the renewal.
- The NCCN network contributes academic-medical-center oncology data covering complex, aggressive and rare cancers under-represented in community-practice records.
- Flatiron's downstream customer book for RWD cohorts includes ~20 global therapeutics developers (Roche, Sanofi and others); renewal terms and any revenue split with NCCN are not disclosed.
Who is involved
New York oncology healthtech; runs an oncology-specific EHR network across community practices and academic medical centers and curates the real-world cancer-data repository being licensed here, with Flatiron Telescope as its new AI intelligence layer.
Founded 2012; acquired by Roche for $1.9B in 2018 and now operates as an independent affiliate of the Roche Group.
Not-for-profit alliance of 34 leading US cancer centers based in Plymouth Meeting, PA; the counterparty whose academic-medical-center network is the source of the real-world data feeding the collaboration.
34 member institutions; founded January 1995; nonprofit, revenue not tracked as a market figure.
The reading
Flatiron does the enrichment: it curates EHR-derived real-world oncology data from the NCCN member cancer centers, applies its quality-dimensions curation process, and now deploys Flatiron Telescope as the AI intelligence layer on top; NCCN's member institutions are the source of the substrate, not the party climbing the enrichment ladder.
The buyer's decision this substrate points at is the next oncology trial design or regulatory submission a drug developer files: NCCN academic-medical-center data adds complex, aggressive and rare cancer cases that community-practice records under-represent, which is exactly the population regulators scrutinise in HTA and single-arm-trial contexts.
What crosses to Flatiron is curated, structured RWD from NCCN sites plus access delivered through Flatiron Telescope; what stays with the member centers is the underlying patient EHR and clinical relationship, and what stays with Flatiron is the curation pipeline and the downstream biopharma customer book.
Not determinable: the renewal terms, grant amounts, and any revenue-share on downstream biopharma licences derived from NCCN-sourced cohorts are not disclosed.
Why it matters
This case looks like a classic academic-network-supplies-data-to-commercial-curator setup, where the AI layer (Telescope) is what changes the enrichability of the substrate and lands the value with Flatiron rather than with the 34 centers. Worth using to show that adding an AI layer on top of an existing collaboration is a capability-stack move made by the party that already owned the climb — not by the substrate's source.
Sources
- businesswire.com — primary
- resources.flatiron.com — party background
- fiercehealthcare.com — party background
- en.wikipedia.org — party background
- nccn.org — party background
Announced 2026-09-09 · Added to the register 2026-09-15